Schedule 13G ownership disclosure
Monte Rosa Therapeutics Inc
Common stock, par value $0.0001 per share · CUSIP: 61225M102
Event date: 2025-04-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SUVRETTA CAPITAL MANAGEMENT, LLC
Shares: 3,360,000.00 · Class: 5.5%
- Averill Master Fund, Ltd.
Shares: 3,147,448.00 · Class: 5.1%
- Aaron Cowen
Shares: 3,360,000.00 · Class: 5.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-25-002493
- Form type
- SCHEDULE 13G
- Filer
- Monte Rosa Therapeutics, Inc.
- CIK
- CIK 1826457
- Filed
- Apr 16, 2025
- Reporting period
- Apr 09, 2025
- Description
- Schedule 13G beneficial ownership